Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL mei 31, 2022
General Nieuws Regulated Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 EN NL mei 25, 2022
General Nieuws Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 EN mei 24, 2022
General Nieuws Regulated Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) EN NL mei 9, 2022
General Nieuws Regulated Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 EN NL mei 6, 2022
General Nieuws Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EN mei 3, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL april 29, 2022
General Nieuws Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EN april 11, 2022
General Nieuws Regulated Oxurion Announces Extraordinary and Annual Shareholders’ Meetings EN NL april 1, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA EN NL maart 30, 2022
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG EN NL maart 17, 2022
General Nieuws Regulated Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement EN NL maart 3, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL februari 22, 2022
General Nieuws Regulated Oxurion NV announces 2021 Full Year Results and 2022 Outlook EN NL februari 22, 2022
General Nieuws Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference EN februari 14, 2022
General Nieuws Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference EN februari 11, 2022
